378 related articles for article (PubMed ID: 15746064)
1. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
[TBL] [Abstract][Full Text] [Related]
2. Role of the microenvironment for radiosensitization by patupilone.
Bley CR; Jochum W; Orlowski K; Furmanova P; Vuong V; McSheehy PM; Pruschy M
Clin Cancer Res; 2009 Feb; 15(4):1335-42. PubMed ID: 19228735
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
[TBL] [Abstract][Full Text] [Related]
5. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
O'Reilly T; McSheehy PM; Wenger F; Hattenberger M; Muller M; Vaxelaire J; Altmann KH; Wartmann M
Prostate; 2005 Nov; 65(3):231-40. PubMed ID: 15948135
[TBL] [Abstract][Full Text] [Related]
6. The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
Oehler C; von Bueren AO; Furmanova P; Broggini-Tenzer A; Orlowski K; Rutkowski S; Frei K; Grotzer MA; Pruschy M
Neuro Oncol; 2011 Sep; 13(9):1000-10. PubMed ID: 21743064
[TBL] [Abstract][Full Text] [Related]
7. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
8. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel sensitizes multidrug resistant cells to radiation.
Mote PA; Davey MW; Davey RA; Oliver L
Anticancer Drugs; 1996 Feb; 7(2):182-8. PubMed ID: 8740723
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
12. Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells.
Rohrer Bley C; Orlowski K; Furmanova P; McSheehy PM; Pruschy M
Lung Cancer; 2011 Sep; 73(3):294-301. PubMed ID: 21333376
[TBL] [Abstract][Full Text] [Related]
13. [Radiosensitization of paclitaxel combined with radiation on nasopharygneal carcinoma cells (CNE-I) in vitro].
Yuan ZY; Yang WZ; Jin J; Gao L; Liu XF; Xu GZ
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):649-52. PubMed ID: 18246791
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells.
Gorodetsky R; Levdansky L; Ringel I; Vexler A
Radiat Res; 1998 Sep; 150(3):283-91. PubMed ID: 9728657
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
[TBL] [Abstract][Full Text] [Related]
17. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
[TBL] [Abstract][Full Text] [Related]
18. Taxol-enhanced cytotoxic effect of radiation in human promyelocytic leukemia cells: relative resistance of multidrug-resistant HL-60 cells in vitro.
Sedlák J; Suliková M; Chorváth M; Hunáková L; Novotný L; Laginová V; Sevcíková L; Boljesiková E; Chorváth B
Neoplasma; 1997; 44(3):172-7. PubMed ID: 9372859
[TBL] [Abstract][Full Text] [Related]
19. Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria.
Khawaja NR; Carré M; Kovacic H; Estève MA; Braguer D
Mol Pharmacol; 2008 Oct; 74(4):1072-83. PubMed ID: 18593821
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
